KALA BIO, INC. Purchase Obligation, to be Paid, Remainder of Fiscal Year
KALA BIO, INC. (KALA) had Purchase Obligation, to be Paid, Remainder of Fiscal Year of $3.03 million as of 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Commitment and Contingencies
us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2022-08-11
- 2022-06-30: Purchase Obligation, to be Paid, Remainder of Fiscal Year $3.03M.
- 2022-03-31: Purchase Obligation, to be Paid, Remainder of Fiscal Year $3.42M.
| Period end | Purchase Obligation, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2022-06-30 | $3.03M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.42M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |